Search
Selected Filters
Filter Results
Displaying 81–90 of 268 research results
-
Jun 25, 2021
The company is planning a late-stage trial for its achromatopsia (CNGB3) gene therapy.
-
Jun 15, 2021
Biogen’s Phase 3 Clinical Trial for its Choroideremia Gene Therapy Doesn’t Meet Endpoints
Additional results from the trial will be reported at a future scientific meeting
-
May 24, 2021
Investigators Report Partial Vision Restoration for One Patient in Optogenetic Therapy Trial
The gene-agnostic approach is designed to restore some vision to people with advanced vision loss
-
May 14, 2021
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
More details from the clinical trial will be reported at a later date
-
May 10, 2021
AGTC Continues to Report Encouraging Data from its Phase 1/2 XLRP Gene Therapy Clinical Trial
The company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy
-
May 10, 2021
Precise and Sensitive Outcome Measures are Essential for Getting Vision Treatments through Clinical Trials
-
May 5, 2021
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Gene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
-
May 3, 2021
ARVO 2021 Highlight: Update on Clinical Trial of jCyte’s Cellular Therapy for RP
Cellular treatment provided significant improvements in visual acuity for subpopulation of patients with better vision
-
Apr 26, 2021
SparingVision to Acquire Therapy for Resurrecting Dormant Cones for Vision Restoration
The gene-agnostic approach shows promise for people with late-stage RP and related diseases.
-
Apr 12, 2021
Encouraging Early Report for Three Patients in LCA1-GUCY2D Gene Therapy Clinical Trial
Development of the emerging gene therapy is being funded by the Foundation’s RD Fund